Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.

[1]  Xueqiang Zhao,et al.  Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment , 2021, Cellular & Molecular Immunology.

[2]  Delphine Potier,et al.  Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy , 2021, Nature Communications.

[3]  Shu Guo,et al.  Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies , 2020, Frontiers in Cell and Developmental Biology.

[4]  H. Kiem,et al.  CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies. , 2020, The Lancet. Haematology.

[5]  D. Zheng,et al.  A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy , 2020, Nature Communications.

[6]  Qian Wu,et al.  Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway , 2020, Acta Pharmacologica Sinica.

[7]  D. Goldstein,et al.  Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. , 2020, Biomaterials.

[8]  Yongping Song,et al.  Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia , 2019, Journal of Hematology & Oncology.

[9]  T. Guo,et al.  Anti-CD19 CAR-T Therapy Bridging to Allo-HSCT for Relapsed/refractory B-cell Acute Lymphoblastic Leukemia: An Open-Label Pragmatic Clinical Trial. , 2019, American journal of hematology.

[10]  Y. A. Wang,et al.  Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. , 2018, ACS nano.

[11]  C. Mackall,et al.  Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.

[12]  L. Emens,et al.  Targeting adenosine for cancer immunotherapy , 2018, Journal of Immunotherapy for Cancer.

[13]  M. Manjili,et al.  IFN‐γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression , 2018, Journal of leukocyte biology.

[14]  Y. Lou,et al.  Cancer immunotherapy beyond immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[15]  G. Coukos,et al.  Cancer immunotherapy full speed ahead. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Carlino,et al.  Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Xuetao Cao,et al.  Evolving strategies for tumor immunotherapy: enhancing the enhancer and suppressing the suppressor , 2017 .

[18]  Zhiqiang Wu,et al.  New development in CAR-T cell therapy , 2017, Journal of Hematology & Oncology.

[19]  E. Zervos,et al.  Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer , 2016, Journal of experimental & clinical cancer research : CR.

[20]  María Martínez-López,et al.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. , 2016, Cancer discovery.

[21]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[22]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.